
VBL Therapeutics (NASDAQ:VBLT) trial of Ofra-Vec did not meet the primary endpoints
VBL Therapeutics (NASDAQ:VBLT) Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer.VBL Therapeutics Shares Are Falling To a […]
75 total views